FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113016864> ?p ?o ?g. }

• W2113016864 endingPage "2320" @default.
• W2113016864 startingPage "2313" @default.
• W2113016864 abstract "To determine whether the addition of intravenous (IV) vinorelbine to epirubicin increased the progression-free survival in first-line treatment of metastatic breast cancer.A total of 387 patients were randomly assigned to receive IV epirubicin 90 mg/m(2) on day 1 and vinorelbine 25 mg/m(2) on days 1 and 8, or epirubicin 90 mg/m(2) IV on day 1. Both regimens were given every 3 weeks for a maximum of 1 year but discontinued prematurely in the event of progressive disease or severe toxicity. In addition, epirubicin was discontinued at a cumulative dose of 1000 mg/m(2) (950 mg/m(2) from June 1999). Prior anthracycline-based adjuvant chemotherapy and prior chemotherapy for metastatic breast cancer was not allowed. Reported results were all based on intent-to-treat analyses.Overall response rates to vinorelbine and epirubicin, and epirubicin alone, were 50% and 42%, respectively (P =.15). The complete response rate was significantly superior in the combination arm (17% v 10%; P =.048) as was median duration of progression-free survival (10.1 months v 8.2 months; P =.019). Median survival was similar in the two arms (19.1 months v 18.0 months; P =.50). Leukopenia related complications, stomatitis, and peripheral neuropathy were more common in the combination arm. The incidences of cardiotoxicity and constipation were similar in both arms.Addition of vinorelbine to epirubicin conferred a significant advantage in terms of complete response rate and progression-free survival, but not in terms of survival." @default.
• W2113016864 created "2016-06-24" @default.
• W2113016864 creator A5023975127 @default.
• W2113016864 creator A5034630560 @default.
• W2113016864 creator A5035537863 @default.
• W2113016864 creator A5053961526 @default.
• W2113016864 creator A5058431388 @default.
• W2113016864 creator A5071541231 @default.
• W2113016864 date "2004-06-15" @default.
• W2113016864 modified "2023-09-23" @default.
• W2113016864 title "Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403)" @default.
• W2113016864 cites W1783154753 @default.
• W2113016864 cites W1796787464 @default.
• W2113016864 cites W1843618725 @default.
• W2113016864 cites W1900639705 @default.
• W2113016864 cites W1918151945 @default.
• W2113016864 cites W1940754997 @default.
• W2113016864 cites W1946018534 @default.
• W2113016864 cites W1973498337 @default.
• W2113016864 cites W1978765248 @default.
• W2113016864 cites W2004454292 @default.
• W2113016864 cites W2013042796 @default.
• W2113016864 cites W2021902088 @default.
• W2113016864 cites W2024003853 @default.
• W2113016864 cites W2025689023 @default.
• W2113016864 cites W2026382780 @default.
• W2113016864 cites W2040900815 @default.
• W2113016864 cites W2041554215 @default.
• W2113016864 cites W2048772541 @default.
• W2113016864 cites W2051297618 @default.
• W2113016864 cites W2064703416 @default.
• W2113016864 cites W2071588876 @default.
• W2113016864 cites W2076545717 @default.
• W2113016864 cites W2078050738 @default.
• W2113016864 cites W2131770017 @default.
• W2113016864 cites W2141056749 @default.
• W2113016864 cites W2144025679 @default.
• W2113016864 cites W2146478870 @default.
• W2113016864 cites W2164203329 @default.
• W2113016864 cites W2169073956 @default.
• W2113016864 cites W2183288147 @default.
• W2113016864 cites W2212225357 @default.
• W2113016864 cites W2270235662 @default.
• W2113016864 cites W2293688022 @default.
• W2113016864 cites W2340435826 @default.
• W2113016864 cites W4241240326 @default.
• W2113016864 cites W562512210 @default.
• W2113016864 doi "https://doi.org/10.1200/jco.2004.11.503" @default.
• W2113016864 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15197192" @default.
• W2113016864 hasPublicationYear "2004" @default.
• W2113016864 type Work @default.
• W2113016864 sameAs 2113016864 @default.
• W2113016864 citedByCount "58" @default.
• W2113016864 countsByYear W21130168642012 @default.
• W2113016864 countsByYear W21130168642013 @default.
• W2113016864 countsByYear W21130168642014 @default.
• W2113016864 countsByYear W21130168642015 @default.
• W2113016864 countsByYear W21130168642016 @default.
• W2113016864 countsByYear W21130168642017 @default.
• W2113016864 countsByYear W21130168642018 @default.
• W2113016864 countsByYear W21130168642019 @default.
• W2113016864 countsByYear W21130168642020 @default.
• W2113016864 countsByYear W21130168642022 @default.
• W2113016864 countsByYear W21130168642023 @default.
• W2113016864 crossrefType "journal-article" @default.
• W2113016864 hasAuthorship W2113016864A5023975127 @default.
• W2113016864 hasAuthorship W2113016864A5034630560 @default.
• W2113016864 hasAuthorship W2113016864A5035537863 @default.
• W2113016864 hasAuthorship W2113016864A5053961526 @default.
• W2113016864 hasAuthorship W2113016864A5058431388 @default.
• W2113016864 hasAuthorship W2113016864A5071541231 @default.
• W2113016864 hasConcept C121608353 @default.
• W2113016864 hasConcept C126322002 @default.
• W2113016864 hasConcept C141071460 @default.
• W2113016864 hasConcept C143998085 @default.
• W2113016864 hasConcept C2775930923 @default.
• W2113016864 hasConcept C2776694085 @default.
• W2113016864 hasConcept C2776802502 @default.
• W2113016864 hasConcept C2778239845 @default.
• W2113016864 hasConcept C2780350996 @default.
• W2113016864 hasConcept C2780835546 @default.
• W2113016864 hasConcept C530470458 @default.
• W2113016864 hasConcept C71924100 @default.
• W2113016864 hasConcept C90924648 @default.
• W2113016864 hasConceptScore W2113016864C121608353 @default.
• W2113016864 hasConceptScore W2113016864C126322002 @default.
• W2113016864 hasConceptScore W2113016864C141071460 @default.
• W2113016864 hasConceptScore W2113016864C143998085 @default.
• W2113016864 hasConceptScore W2113016864C2775930923 @default.
• W2113016864 hasConceptScore W2113016864C2776694085 @default.
• W2113016864 hasConceptScore W2113016864C2776802502 @default.
• W2113016864 hasConceptScore W2113016864C2778239845 @default.
• W2113016864 hasConceptScore W2113016864C2780350996 @default.
• W2113016864 hasConceptScore W2113016864C2780835546 @default.
• W2113016864 hasConceptScore W2113016864C530470458 @default.
• W2113016864 hasConceptScore W2113016864C71924100 @default.
• W2113016864 hasConceptScore W2113016864C90924648 @default.
• W2113016864 hasIssue "12" @default.

• next